A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma.

Trial Profile

A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2013

At a glance

  • Drugs Everolimus (Primary) ; Panobinostat (Primary)
  • Indications Chronic lymphocytic leukaemia; Hodgkin's disease; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Apr 2012 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 14 Oct 2011 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top